Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

BACKGROUND: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. METHODS: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individ...

Descripción completa

Detalles Bibliográficos
Autores principales: Blum, Vinicius Fontanesi, Cimerman, Sérgio, Hunter, James R, Tierno, Paulo, Lacerda, Acioly, Soeiro, Alexandre, Cardoso, Florentino, Bellei, Nancy Cristina, Maricato, Juliana, Mantovani, Nathalia, Vassao, Marcella, Dias, Danilo, Galinskas, Juliana, Janini, Luis Mário Ramos, Santos-Oliveira, Joanna Reis, Da-Cruz, Alda Maria, Diaz, Ricardo Sobhie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235996/
https://www.ncbi.nlm.nih.gov/pubmed/34222847
http://dx.doi.org/10.1016/j.eclinm.2021.100981

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235996/
https://www.ncbi.nlm.nih.gov/pubmed/34222847
http://dx.doi.org/10.1016/j.eclinm.2021.100981

Ejemplares similares